XRCC2 and cancer: Specifically, EGFR is a widely studied oncogene with a potential role in cancer therapeutics [48], six are core genes (AURKA, CDK1, CDT1, PRKDC, RAD51, and XRCC2), six are potential drug targets, and five were identified as drug actionable genes.